Home > Management Dialogue
Kevin Nelson TissueGen

Kevin Nelson
Chief Scientific Officer , TissueGen

Kevin Nelson, Chief Scientific Officer, TissueGen discusses the growing potential of biodegrable fibres and its application in the field of biomedical textiles.

Can you tell us about your latest innovation, the Elute Fibre?
Kevin Nelson
Launched in 2013, Elute fibre is enabling development of medical devices that may revolutionise the treatment of many indications throughout the body.

By delivering sensitive pharmaceuticals and biologics directly at the surgical site, Elute Fibre may enable treating physicians to orchestrate the body's response and guide the healing and regenerative processes.
Which are the core areas that you work on in technical textiles? What is the growth potential in each niche?
Kevin Nelson
Elute enables controlled, sustained delivery of the broadest range of drugs from biodegradable fibres. This technology has far-reaching implications for enabling the advancement of clinical applications in advanced drug delivery, nerve regeneration and tissue engineering.

Based on market size and adoption rates, we see significant growth potential in the orthopedic applications segment. Elute fibre is uniquely suited for delivering sensitive biologics over extended release profiles, from orthopedic sutures to other implantable devices.
Which are your biggest markets? Where does Asia feature in your growth strategy? Which are the countries looking for more technical textile?
Kevin Nelson
TissueGen currently focuses on opportunities in the United States of America and European markets. However, Asia is home to many innovative textile companies and we anticipate opportunities for growth in this market.
How has your business grown in the last two years? What is your target growth for the next two years?
Kevin Nelson
The year 2015 marked our strongest annual revenue. Over the past 12 months, we increased our team by 150 per cent. Both are significant milestones. Based on demand we are seeing, we expect the current trend to continue in 2016 and beyond.
What percentage of profits do you earmark for R&D annually?
Kevin Nelson
We have invested heavily in the development of Elute fibre for over a decade and continue to dedicate significant resources towards quality improvements and application development for this innovative technology.
Which are your sourcing hubs for raw materials?
Kevin Nelson
We source polymer, drug and chemical components primarily from leading suppliers in the United States of America and Europe.
What new applications do you foresee in the near future for biomedical textiles and for your segment?
Kevin Nelson
We expect to see significant growth and new opportunities for Elute fibre related to sutures, orthopedic applications and nerve repair.
What are the trends in your segment and what new developments can be expected from this field?
Kevin Nelson
TissueGen's Elute fibre is on the leading edge of the medical industry's adoption of implantable drug delivery and the development of biodegradable medical devices. We anticipate deployment of novel new treatments for indications from head to foot.
What is the most revolutionary work by TissueGen that has changed the industry?
Kevin Nelson
Early pre-clinical data indicates Elute fibre and our licensed, patent-pending technology for chemical gradients may enable regeneration of injured nerves. Though early, this approach could potentially aid in the treatment of spinal cord injuries.
View comments on this interview Published on : 18 Apr 2016
Print Interview   |   Forward Link to friend   |   Bookmark and Share
Name Company
Designation Email
Country Phone/Mobile
Character Left:

Note : www.technicaltextile.net/ will publish as many comments as possible but cannot guarantee publication of all. www.technicaltextile.net/ also holds all rights reserved to omit/edit/upload the comments for reasons of clarity, brevity and morality.

Featured Partner

Marcel Alberts Marcel Alberts
Managing Director

Coating at a fibre level is a practice not usually seen in the high-performance fibres industry, des ...
Suresh Patel Suresh Patel
Managing Director
Sidwin Fabric

Sidwin Fabric is a manufacturer and exporter of polypropylene textiles and a wide range of nonwoven ...
Lynda Kelly Lynda Kelly
Senior Vice President
Suominen Corporation

Suominen Corporation is a manufacturer of nonwovens as roll goods for wipes and for hygiene products ...
Kerem Durdag Kerem Durdag
Biovation II LLC

Kerem Durdag, CEO, Biovation II LLC, provides an insight into future innovations in nonwoven healthc ...
Urs Stalder Urs Stalder
Sanitized AG

Urs Stalder, CEO, Sanitized AG, talks about the increasing use of hygiene functions in textile produ ...

Esteemed Clients

Everything is about to change. Stay Tuned !